Showing results (81-90 of 103) with videos related to
Sort By:
Pageof 11
Breast Cancer Research and Treatment|January 12, 2008
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesDavid Cameron, Michelle Casey, Michael Press, et al.NPJ Breast Cancer|September 14, 2017
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registrySalomon M Stemmer, Mariana Steiner, Shulamith Rizel, et al.Breast Cancer Research and Treatment|April 19, 2020
Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variantsRinat Bernstein-Molho, Eitan Friedman, Inbal Kedar, et al.The Lancet. Oncology|August 11, 2020
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket studySusan M Domchek, Sophie Postel-Vinay, Seock-Ah Im, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO StudyNicholas C Turner, Judith Balmaña, Coralie Poncet, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2015
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31Karen A Gelmon, Frances M Boyle, Bella Kaufman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2013
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional studyJoo Ern Ang, Charlie Gourley, C Bethan Powell, et al.JAMA Oncology|January 22, 2021
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical TrialHope S Rugo, Seock-Ah Im, Fatima Cardoso, et al.Breast Cancer Research and Treatment|May 5, 2011
Evidence for a link between TNFRSF11A and risk of breast cancerNúria Bonifaci, Marta Palafox, Pasquale Pellegrini, et al.The New England Journal of Medicine|June 3, 2021
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast CancerAndrew N J Tutt, Judy E Garber, Bella Kaufman, et al.Pageof 11